The rising prevalence of allergies represents an increasing socioeconomic burden. A detailed understanding of the immunological mechanisms that underlie the development of allergic disease, as well as the processes that drive immune tolerance to allergens, will be instrumental in designing therapeutic strategies to treat and prevent allergic disease.

Improved characterization of individual patients through the use of specific biomarkers and improved definitions of disease endotypes are paving the way for the use of targeted therapeutic approaches for personalized treatment. Allergen-specific immunotherapy and biologic therapies that target key molecules driving the Th2 response are already used in the clinic, and a wave of novel drug candidates are under development. In-depth analysis of the cells and tissues of patients treated with such targeted interventions provides a wealth of information on the mechanisms that drive allergies and tolerance to allergens. Here, we aim to deliver an overview of the current state of specific inhibitors used in the treatment of allergy, with a particular focus on asthma and atopic dermatitis, and provide insights into the roles of these molecules in immunological mechanisms of allergic disease.

Find the latest version:
http://jci.me/124607/pdf
The use of biologics for immune modulation in allergic disease

Willem van de Veen and Mübeccel Akdis

Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland. *Christine Kühne – Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.

The rising prevalence of allergies represents an increasing socioeconomic burden. A detailed understanding of the immunological mechanisms that underlie the development of allergic disease, as well as the processes that drive immune tolerance to allergens, will be instrumental in designing therapeutic strategies to treat and prevent allergic disease. Improved characterization of individual patients through the use of specific biomarkers and improved definitions of disease endotypes are paving the way for the use of targeted therapeutic approaches for personalized treatment. Allergen-specific immunotherapy and biologic therapies that target key molecules driving the Th2 response are already used in the clinic, and a wave of novel drug candidates are under development. In-depth analysis of the cells and tissues of patients treated with such targeted interventions provides a wealth of information on the mechanisms that drive allergies and tolerance to allergens. Here, we aim to deliver an overview of the current state of specific inhibitors used in the treatment of allergy, with a particular focus on asthma and atopic dermatitis, and provide insights into the roles of these molecules in immunological mechanisms of allergic disease.

Immunological mechanisms of allergy and tolerance

Allergic sensitization and type 1 and IV hypersensitivity reactions.

Allergies develop as a result of an immune response to distinct environmental protein antigens, called allergens. In recent years, substantial progress has been made in elucidating mechanisms that drive the initiation and persistence of allergic reactions. Development of allergic diseases starts with a sensitization phase (Figure 1). Key processes driving allergic sensitization include activation and maturation of dendritic cells (DCs) upon contact with allergens, epithelial alarmins, and infectious agents, followed by clonal expansion of allergen-specific Th2 cells that are polarized toward producing type 2 cytokines, including IL-4, IL-5, IL-9, IL-13, IL-25, IL-31, IL-33, and thymic stromal lymphopoietin (TSLP) (1). Th2 cells induce class switch recombination of B cells to the IgE isotype and differentiation to IgE-producing plasma cells. IgE can bind to the high-affinity IgE receptor FcεRI on basophils and mast cells. Moreover, IgE can also enhance allergen uptake and presentation through so-called facilitated antigen presentation (2, 3). These processes form the basis of allergic sensitization.

Subsequent exposure to the culprit allergen can trigger IgE-mediated FcεRI cross-linking on mast cells and basophils, leading to a type I hypersensitivity reaction. During the early phase of this reaction, which starts within minutes after allergen exposure, mast cells and/or basophils degranulate and release a range of preformed and newly synthesized mediators including histamine, leukotrienes, heparin, and several proteases, as well as cytokines and growth factors such as TNF-α and VEGFA (4). After 2 to 6 hours of exposure, the late phase of the reaction manifests, characterized by edema, erythema in skin, and airway narrowing and mucus secretion in the airways. These symptoms are caused by the recruitment and activation of Th2 cells, eosinophils, basophils, and tissue-resident mast cells. Persistent allergen exposure can produce a chronic phase of inflammation that represents a distinct Th2 type of type IV hypersensitivity (5). Classical type IV hypersensitivity denotes tuberculin-type hypersensitivity with the involvement of Th1 cells. In allergic inflammation a cellular late-phase response develops, characterized by tissue inflammation with eosinophils, Th2 cells, and type 2 innate lymphoid cells (ILC2s); remodeling of vasculature and smooth muscle cells; and extracellular matrix formation and fibrosis (4, 5). In the clinical setting, this chronic inflammation prevails and forms the basis for the main tissue inflammation mechanisms referred to as Th2 or type 2 inflammation in asthma, atopic dermatitis (AD), chronic rhinosinusitis (CRS) with nasal polyps, and allergic rhinitis. Notably, approximately 20% of pediatric and adult AD patients and 10% to 20% of pediatric and 50% of adult asthma patients show a non-allergic and non-eosinophilic phenotype. Most of the CRS without nasal polyps patients also fall into this non-type 2 category. So far, these non-type 2 diseases have not been efficiently targeted with biologics, and their pathogenetic mechanisms are associated with a broad range of environmental and/or host factors, such as smoking, exposure to pollutants, work-related agents, chronic infections, and obesity (6).

Mechanisms of immune tolerance to allergens. In recent years, substantial efforts have been made to improve the classification of patients suffering from allergic disease in order to facilitate the development of personalized medicine. A key concept in this regard comes from the determination of so-called disease...
endotypes, which describe a subtype of a disease condition defined by distinct pathophysiological mechanisms, in contrast to disease phenotypes, which define disease characteristics without implying a mechanism. Identification of biomarkers that accurately and objectively examine pathogenic processes and responses to therapeutic interventions is critical for the development of individual therapies. The term “theratype” has been coined to describe subsets of patients that respond well to a certain therapeutic intervention (7–12).

The induction of immune tolerance involves molecular mechanisms of anergy, deletion, suppression, immune privilege, and ignorance. This Review mainly focuses on immunological mechanisms of peripheral tolerance to allergens. Various models have been used to study the mechanisms that drive immune tolerance to allergens. These include the in-depth analysis of immunological parameters in allergic patients treated with allergen-specific immunotherapy (AIT) and in healthy individuals who are chronically exposed to high-doses of allergens, such as cat owners and nonallergic beekeepers (13, 14). Early desensitization of mast cells and basophils (15), induction of regulatory T (13, 16–18) and B cells (19–22), anergy in Th2 cells, and probably apoptosis of highly activated Th2 cells (23), suppression of eosinophil activation and migration (24), and production of allergen-specific IgG4 antibodies (25, 26) are key processes in the development of immune tolerance in response to AIT (27). In humans most of these findings are correlative, but a recent study reported that anti–Fel d 1–IgG4 mAb injection induced the cat allergen–blocking antibody effect within a week to the same extent as did AIT (28). Knowledge obtained from these studies paved the way for the development of diagnostic tools and innovative drugs, particularly biologics that specifically target select mediators of allergic immune responses (7, 27, 29, 30). To date there is no direct evidence that any of the biologics discussed in this Review induce allergen tolerance; however, their usage together with immune tolerance–inducing AIT is open for further studies.

Targeting the mediators of the allergic response

Improved understanding of the immunological mechanisms that regulate allergy development and allergen tolerance allows a systematic strategy for drug design aimed at targeting specific molecules with a known or suspected role in these processes. The feedback from preclinical work and clinical trial results provide an invaluable data resource to further elucidate these mechanisms. Here, we describe the major strategies aimed at prevention and treatment of allergic disease and discuss the insights they provide into the immunological mechanisms of allergy and tolerance.

Recent advances in the field of therapeutic antibodies have led to the development of a wide range of biologic drug candidates (mostly mAbs) for the treatment of allergic diseases (listed in Table 1). These can be broadly grouped into two distinct groups: (a) biologics targeting cytokines and cytokine receptors, and (b) biologics targeting soluble and membrane-bound IgE.
Targeting classical Th2 effectors using IL-4/IL-13 interference

IL-4 and IL-13 are structurally and functionally related cytokines that display approximately 25% sequence homology. Both are composed of four α-helix bundles. These cytokines are pivotal for both IgE sensitization and late-phase allergic responses. IL-4 and IL-13 share many functional characteristics, including their capacity to induce IgE class switch recombination (albeit only in humans, as IL-13 cannot induce IgE in mice), airway hyperreactivity, mucus production, goblet cell hyperplasia, smooth muscle cell contraction, and airway remodeling (1, 31).

Both IL-4 and IL-13 are produced by Th2 cells, basophils, mast cells, and NKT cells. ILC2s can also produce small amounts of IL-4, but their capacity to produce IL-13 is much higher (1, 32). IL-4 signals through receptors consisting of heterodimers of the IL-4Rα and the common Y chain and through receptors comprising a heterodimer of IL-4Rα chain and IL-13Rα1 or IL-13Rα2, a signaling pathway it shares with IL-13 (Figure 2 and ref. 1). The fact that IL-4 and IL-13 share a receptor explains their large functional overlap. Several drugs targeting IL-4, IL-13, and their common receptor have been developed. However, so far only dupilumab, an mAb targeting IL-4Rα, has proven efficacious, and it has been licensed for the treatment of AD (33) and asthma (34–37). These findings suggest that inhibiting both IL-4 and IL-13 is necessary for clinically successful results, but it should be noted here that unsuccessful studies cannot rule out any relevant molecular mechanisms, because these drugs depend on many pharmacodynamic factors, such as dose, affinity, half-life, etc. A clinical study in 2000 showed that a single dose of anti-IL-5 mAb decreased blood eosinophils for up to 16 weeks and sputum eosinophils at 4 weeks, which has considerable therapeutic potential for asthma and allergy. However, the data did not support the treatment effect of anti-IL-5 mAb for late asthmatic response and airway hyperresponsiveness (38).

Dupilumab’s use for other applications is currently being explored. Promising results have been obtained for patients with chronic sinusitis and nasal polyposis (39, 40). A recent case report described the successful treatment of a recalcitrant bullous pemphigoid patient with dupilumab (41). Several other biologics have been developed to target IL-4Rα (42, 43). Among these is pitrakinra (trade name Aerovant), a biologic drug that, in contrast to other biologics targeting the IL-4/IL-13 pathway, is not an mAb. Pitrakinra is a recombinant IL-4 that contains two targeted point mutations and functions as an antagonist of IL-4Rα (44, 45). Thus, its expected mode of action is analogous to that of dupilumab. Inhalation treatment of asthma patients with pitrakinra did not show an overall significant improvement of asthma exacerbations (45). Interestingly, a subgroup analysis revealed that patients with a specific SNP (rs8832GG) in the 3′-untranslated region of the IL4RA gene did significantly improve exacerbations.

Table 1. Biologic drug candidates for the treatment of allergic diseases

<table>
<thead>
<tr>
<th>Target</th>
<th>Biologic</th>
<th>Type of drug</th>
<th>Effect on disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-4Rα</td>
<td>Dupilumab</td>
<td>mAb</td>
<td>Efficacious for atopic dermatitis and asthma</td>
</tr>
<tr>
<td>IL-4Rα</td>
<td>Pitrakinra</td>
<td>Mutated IL-4 molecule</td>
<td>No significant improvement of asthma exacerbations but efficacious in a subgroup of asthma patients with a specific SNP in the IL4RA gene</td>
</tr>
<tr>
<td>IL-13</td>
<td>Lebnikizumab</td>
<td>mAb</td>
<td>No significant improvement of asthma exacerbations but efficacious in a subgroup of patients with high serum periostin levels</td>
</tr>
<tr>
<td>IL-4/IL-13</td>
<td>QBX258</td>
<td>Combination of mAbs targeting IL-4 and IL-13</td>
<td>No results published yet</td>
</tr>
<tr>
<td>IL-5</td>
<td>Mepolizumab</td>
<td>mAb</td>
<td>Efficacious for treatment of severe eosinophilic asthma; reduced need for surgery in severe nasal polyposis patients; reduction in blood and esophageal eosinophilia in EoE patients</td>
</tr>
<tr>
<td>IL-5</td>
<td>Reslizumab</td>
<td>mAb</td>
<td>Efficacious for treatment of severe eosinophilic asthma</td>
</tr>
<tr>
<td>IL-5Rα</td>
<td>Benralizumab</td>
<td>mAb</td>
<td>Efficacious for treatment of severe eosinophilic asthma</td>
</tr>
<tr>
<td>IL-9</td>
<td>Enokizumab</td>
<td>mAb</td>
<td>No significant improvement of asthma symptoms</td>
</tr>
<tr>
<td>IL-31</td>
<td>BMS-981164</td>
<td>mAb</td>
<td>No results published yet</td>
</tr>
<tr>
<td>IL-31</td>
<td>Nemolizumab</td>
<td>mAb</td>
<td>Significantly reduced the level of pruritus in patients with moderate to severe AD</td>
</tr>
<tr>
<td>TSLP</td>
<td>Tezepelumab</td>
<td>mAb</td>
<td>Efficacious for treatment of allergic asthma; no significant improvement in atopic dermatitis patients</td>
</tr>
<tr>
<td>IL-33</td>
<td>Etohumab</td>
<td>mAb</td>
<td>Trials ongoing for treatment of peanut allergy, atopic dermatitis, allergic asthma, chronic rhinosinusitis with nasal polyps</td>
</tr>
<tr>
<td>IL-33</td>
<td>MEDI3506</td>
<td>mAb</td>
<td>Trial ongoing for treatment of chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>IL-33R (ST2)</td>
<td>RG 6149/AMG 282</td>
<td>mAb</td>
<td>Trial in chronic rhinosinusitis with nasal polyps completed, no results published; trial ongoing for treatment of chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>IgE</td>
<td>Omalizumab</td>
<td>mAb</td>
<td>Efficacious for treatment of allergic asthma and spontaneous urticaria</td>
</tr>
<tr>
<td>IgE</td>
<td>Ligelizumab</td>
<td>mAb</td>
<td>Efficacious for treatment of allergic asthma</td>
</tr>
<tr>
<td>IgE</td>
<td>Quilizumab</td>
<td>mAb</td>
<td>Reduction in serum IgE but no significant reduction in asthma exacerbations</td>
</tr>
<tr>
<td>IgE</td>
<td>MEDI4212</td>
<td>mAb</td>
<td>Rapid but short-lived reduction in IgE</td>
</tr>
</tbody>
</table>

The Journal of Clinical Investigation
IL-4 (dectrekumab, also known as VAK 694) and anti–IL-13 (QAX576, listed under the name QBX258) agents. This approach has the potential to tackle the redundancy problem, but results have not yet been published.

Interfering with eosinophil responses by targeting IL-5

IL-5 is produced by Th2 cells, mast cells, NKT cells, activated eosinophils, and ILC2s (50–53). It binds to IL-5R, a heterodimeric receptor composed of an IL-5Rα subunit responsible for binding IL-5 and the common β chain responsible for signaling. IL-5R is expressed on eosinophils, basophils, mast cells, and B cells (Figure 2). The common β chain is also responsible for IL-3 and GM-CSF signaling (1). Eosinophils inflict tissue damage by degranulating and secreting a range of mediators including histamine, arylsulfatase, eosinophil peroxidase, and others (54). Because of its potent induction of eosinophil activation, survival, and proliferation, IL-5 contributes substantially to the development of allergic airway inflammation in asthma (1, 55). This also makes it an attractive target for therapeutic intervention.

Several biologics directly target IL-5 itself (mepolizumab and reslizumab) or IL-5Rα (benralizumab) (55). All three drugs were found to reduce the rate of asthma exacerbations in patients with severe eosinophilic asthma by approximately half and are now approved for the treatment of eosinophilic asthma (56–61). Long-term intravenous application of reslizumab produced sustained improvements in lung function and asthma exacerbations for up to 2 years in patients with moderate to severe eosinophilic asthma (62).

Identification of accurate predictive biomarkers to identify which patients will respond to therapy will help to further improve the success of treatment with such IL-5–targeting biologics. Patients with a count of ≥150 eosinophils per microliter displayed the strongest reduction in asthma exacerbation upon treatment with mepolizumab (63). Anti–IL-5 or anti–IL-5Rα therapy was also investigated in other patient groups that suffer from eosinophil-associated diseases. Patients with eosinophilic nasal polyposis who were treated with mepolizumab every 4 weeks for 25 weeks were less likely to require surgery as a treatment for their condition (64). Another condition that may benefit from anti–IL-5 therapy is eosinophilic esophagitis (EoE). Anti–IL-5 therapy led to marked decreases in peripheral blood and esophageal eosinophilia in EoE patients and improved clinical outcomes in both adults and children (65–67) in some studies, but (45). Therefore, this genetic variant could be considered a biomarker for patients with a high likelihood of responding to this treatment. Contemporaneous with this trial, a successful phase II trial with lebrikizumab (an anti–IL-13 mAb) for treatment of asthma indicated the secreted protein periostin as a biomarker for patient selection (46); however, lebrikizumab did not show efficacy in a multicenter phase III trial (47).

Several biologics that directly target IL-4 or IL-13, rather than their receptors, have failed to meet their clinical endpoints in asthma (43, 48, 49). The main reason for this most likely stems from the large degree of redundancy in biological function between IL-4 and IL-13. A recent study (NCT01479595; ClinicalTrials.gov) assessed the efficacy of treating asthma patients with a combination of anti-
Interfering in IL-9–mediated Th2 and mast cell responses

IL-9 is produced by Th2 cells, ILC2s, Th9 cells, and granulocytes (including basophils, eosinophils, and possibly neutrophils), as well as as mast cells (70–76). It signals through the IL-9 receptor complex, comprising an IL-9Rα chain and the common γ chain (γc), which is expressed on B and T cells, epithelial cells, and mast cells (Figure 2 and ref. 1). IL-9 plays a role in allergic disease by promoting IgE production by B cells, chemokine production and mucus secretion by epithelial cells, and mast cell proliferation (77, 78). The anti–IL-9 mAb enokizumab (MEDIS28) has been evaluated in moderate to severe asthma but failed to demonstrate an improvement in any of the trials (79). The impressive effects of IL-9 in mouse models was not replicated in human asthma. Further studies could possibly identify subgroups of patients with distinct asthma endotypes that may benefit from anti–IL-9 therapy. Anti–IL-9 could also be considered in the context of a combination therapy together with AIT: OVA-sensitized mice treated with an oral immunotherapy regimen and anti–IL-9 therapy. Anti–IL-9 could also be considered in the combination therapy together with AIT: OVA-sensitized mice treated with an oral immunotherapy regimen and anti–IL-9 therapy.

Fighting the itch response by targeting IL-31

IL-31 is produced mainly by Th2 cells and to a lesser extent by CD8+ T cells. It signals through a heterodimeric receptor consisting of IL-31Rα and oncostatin M receptor β, which is expressed by keratinocytes, epithelial cells, eosinophils, basophils, monocytes, and dorsal root ganglia (Figure 2 and refs. 81, 82). It has been shown to promote Th2-driven inflammation (83). The main property of IL-31 that gives it a unique role is its ability to induce pruritus in conditions such as AD (82). This is most likely related to the fact that the IL-31 receptor complex is expressed at high levels on dorsal root ganglia, where the cell bodies of cutaneous neurons are located.

Currently two mAbs that target IL-31 signaling are under development. BMS-981164 binds IL-31, while nemolizumab is directed against IL-31Rα (82). A phase I trial of BMS-981164 in AD patients was completed in 2015 (NCT01614756), but no results have been published yet. A phase II trial demonstrated that subcutaneous monthly treatment with nemolizumab significantly reduced the level of pruritus after 3 months in patients with moderate to severe AD (84). A later study showed that this beneficial effect was maintained for up to 64 weeks (85). Interestingly, an experiment in which healthy controls and AD patients were challenged with topical IL-31 by skin prick testing showed no direct induction of itch at the provocation site in most individuals, while a late-onset itch response, with a delay of over 2 hours, was reported by 9 of 30 subjects. This suggests that IL-31 may exert its pruritic effects indirectly through keratinocyte activation rather than directly through interaction with cutaneous nerves (86).

Targeting IL-25–, IL-33–, and TSLP-mediated epithelium–immune cell interactions

Epithelial cells are instrumental in orchestrating allergic immune responses. They are an important source of the Th2-inducing cytokines IL-25, IL-33, and TSLP (87). Considerable efforts have been made to elucidate the distinct roles of IL-25, IL-33, and TSLP in both early and late phases of allergic responses. Exposure to allergens, infections, or tissue damage can promote the release of these cytokines from the epithelium. Early priming of the allergen-specific immune responses with these cytokines may play an important role in the development of Th2 priming by DCs and type 2 ILCs. Decreased production of these cytokines represents an important target for the priming of type 2 immune responses as discussed below. Currently, IL-33 and TSLP are promising targets, but IL-25–related studies are not ongoing on a large scale. This may be due to more exhaustive effects of IL-33 and TSLP in vivo and in vivo studies compared with IL-25, although further studies are needed (88).

IL-25. IL-25 (also referred to as IL-17E) is produced by epithelial cells in the gut, lung, and sinuses, as well as by Th2 cells, basophils, mast cells, and eosinophils (1, 89). Recent studies demonstrated that intestinal tuft cells constitutively produce IL-25 to sustain ILC2 homeostasis in the murine lamina propria (90). IL-25 binds to a heterodimeric receptor consisting of IL-17RA and IL-17RB (Figure 2). IL-25 induces secretion of IL-4, IL-5, and IL-13 from
Th2 cells and induces IL-5 and IL-13 secretion from ILC2s (89). Therefore, IL-25 is a promising drug target for allergic disease. Several studies have demonstrated the potential of IL-25 neutralization in the context of allergic airway inflammation and CRS with nasal polyps, but human therapeutics targeting IL-25 are not yet in clinical development (91, 92).

Neutralization of IL-25 during the sensitization phase in a murine model of allergic airway inflammation significantly reduced IL-5 and IL-13 production, reduced eosinophil inflammation and IgE production, and prevented allergic airway hyperresponsiveness (AHR). When administered during the challenge phase, anti–IL-25 could also prevent AHR, indicating that IL-25 may also play a role during the effector phase of the allergic response (93).

**TSLP.** TSLP is a member of the IL-2 cytokine family that is produced by epithelial cells of the skin, gut, and lung (94, 95). Basophils, mast cells, and DCs have also been shown to produce TSLP (96–98). TSLP has two isoforms, of which the short isoform is constitutively expressed, while the long isoform is released in response to pathogen exposure, TLR engagement, and stimulation with cytokines such as IL-4, IL-13, IL-1β, and TNF-α. The heterodimeric receptor for TSLP, which is composed of the TSLP receptor (TSLPR) and IL-7Rα, is expressed by DCs, monocytes, B cells, mast cells, and ILC2s (Figure 2 and ref. 99). DCs and ILCs are considered prime target cells for TSLP in the context of allergic responses (100–102). TSLP-stimulated DCs upregulate OX40L, CD80, and CD86 and induce Th2 differentiation from naive CD4+ T cells (103). Since TSLP acts on DCs that prime Th2 cells, blocking TSLP is expected to reduce the development or enhancement of Th2 responses. TSLP is upregulated in airways of asthma patients, and it was found that an SNP in the TSLP locus was associated with protection from asthma (104, 105).

The TSLP-targeting therapeutic antibody tezepelumab (AMG 157) is currently under investigation for the treatment of asthma and AD. A phase I trial in 31 patients with mild allergic asthma showed that three monthly doses of tezepelumab attenuated most measures of allergen-induced early and late asthmatic responses. This was associated with decreases in blood and sputum eosinophils and exhaled nitric oxide (106). In a phase II study of tezepelumab for the treatment of AD, improvements over placebo were not statistically significant (107). A phase II trial with a duration of 1 year assessing the efficacy and safety of monthly treatment with tezepelumab in patients with uncontrolled asthma showed a significant reduction in asthma exacerbations as well as improved lung function. This clinical improvement was independent of eosinophil counts at baseline (108). Tezepelumab is also currently being tested in combination with AIT with the aim of enhancing the efficacy of immune tolerance with this number of patients. A recent phase IIa proof-of-concept trial for the treatment of moderate to severe AD demonstrated that a single dose of tezepelumab led to decreased clinical severity (demonstrated by 50% reduction of the eczema area and severity index [EASI] score 57 days after treatment). This was associated with a decrease in circulating eosinophils and IL-33–mediated IFN-γ release (NCT03533751) (116). Tezepelumab is currently also being investigated in phase II clinical trials for its effect on CRS with nasal polyps (NCT03614923) and severe eosinophilic asthma (NCT03469934). MED13506 is currently being tested in a phase I trial for chronic obstructive pulmonary disease (COPD) (NCT03096795). The anti-ST2 drug candidate RG 6149/AMG 282 has been tested in a phase I trial in CRS patients with nasal polyps, but no results have been published (NCT02170337). Moreover, recruitment for a phase II trial for treatment of COPD is ongoing (NCT03615040). Given the potential functional redundancy of TSLP, IL-25, and IL-33 in the induction of Th2 responses, which is not caused by molecular or signaling pathway similarity, isolated neutralization of these molecules may fail to yield the desired clinical effect. In a murine model of helminth infection and chronic lung inflammation, neutralizing TSLP, IL-25, or IL-33 individually did not prevent the development of Th2-dependent inflammation and fibrosis (117). Only simultaneous blockade of all three mediators...
led to reductions in eosinophils, fibrosis, and ILC2s. Similar results were found in a model of house dust mite–induced allergic airway hypersensitivity (117). These data indicate that monotherapy targeting individual cytokines may not be sufficient in certain cases of progressive type 2–driven disease, and combination therapy could be considered. While these preclinical studies targeting TSLP, IL-33, and IL-25 simultaneously showed a superior effect on the inhibition of Th2 responses, it should noted here that combination therapy with three new biologics in humans is currently not possible. The increased complexity associated with the use of combinations of novel biologics may lead to unexpected side effects and increased toxicity. One innovative approach that is being pursued is the design of novel highly potent bispecific anti–TSLP/IL-13 antibodies called Zweimabs (monovalent bispecific) and Doppelmabs (bivalent bispecific) that concurrently inhibit signaling by these two cytokines (118).

**Targeting IgE and IgE-expressing B cells**

Because of its key role in type I hypersensitivity reactions, IgE has always been a prime target for intervention in allergic disease. This has been approached from two different angles: (a) targeting soluble IgE and (b) targeting B cells that express surface IgE (119). Another less specific approach for targeting IgE production has been the depletion of all B cells using the anti–CD20 antibody rituximab (Figure 3).

Despite its critical role in allergies, surprisingly little is known regarding the regulation of IgE production in humans. This fact relates primarily to the extremely low frequency of IgE-switched memory B cells. It remains challenging to accurately detect and purify these cells from humans. A large body of research has convincingly demonstrated that IgE production is highly dependent on Th2 responses, in particular IL-4 and IL-13 signaling (120). The main question that still remains incompletely answered pertains to the location of IgE memory. Which cells form the basis of IgE memory? This is a critical issue, because these cells should be targeted to efficiently eliminate allergen-specific IgE. There are three possible major cell types that could form a reservoir for the IgE memory response: (a) IgE-switched memory B cells, (b) long-living plasma cells that primarily reside in the bone marrow (121), and (c) memory B cells that switched to any isotype within the IgH (immunoglobulin heavy chain) locus located between IgHD and IgHE (in humans these are IgG3, IgG1, IgA1, IgG2, and IgG4, and in mice, IgG3, IgG1, IgG2b, and IgG2a), because these cells can develop into IgE-switched B cells through a process called sequential class switch recombination (122, 123). Our ability to design the optimal strategy for targeting IgE memory responses will strongly improve if we can define which IgH isotype is the major contributor to IgE memory.

Currently, omalizumab is the only efficacious IgE-targeting antibody licensed for the treatment of allergic asthma and chronic spontaneous urticaria (124–130). Preliminary data indicate that patients suffering from systemic mastocytosis may also benefit from omalizumab treatment (131). Omalizumab binds soluble IgE, thereby preventing its binding to IgE receptors on effector cells (Figure 3). Interestingly, omalizumab treatment also leads to a reduction of FcεRI on mast cells, basophils, and DCs (132). Omalizumab is currently being tested for a wide range of allergic conditions and other pathologies (133). An additional anti–IgE antibody, ligelizumab (QGE031), that binds the Cε3 domain of IgE with higher affinity than omalizumab is currently in clinical testing (Figure 3). Ligelizumab was found to have a larger suppressive effect than omalizumab on circulating IgE, basophil FcεRI expression, and skin prick test responses to allergens (134). A controlled trial in 37 mild allergic asthma patients demonstrated that ligelizumab has greater efficacy than omalizumab against inhaled and skin allergic responses (135). However, both antibodies neutralize serum IgE without affecting IgE production by plasma cells. While this type of approach neutralizes IgE-mediated type I hypersensitivity reactions, it has no impact on the IgE production, necessitating treatment at regular intervals of 2–4 weeks (125). Clinical studies are ongoing for urticaria (NCT03437278, NCT02649218).

An alternative strategy to interfere with IgE production involves the use of antibodies that bind to the membrane-bound form of IgE, thereby targeting B cells expressing an IgE B cell receptor (BCR). Quilizumab (MEMP1972A/RG7449) is a humanized mAb that binds to the M1′ segment of IgE (136). This segment is only present on membrane IgE and not on free, soluble IgE (137). Therefore,quilizumab targets IgE+ memory B cells and plasmablasts, while long-lived IgE-switched plasma cells, which do not express surface IgE, are not targeted (Figure 3). Preclinical studies demonstrated that targeting the M1′ domain of IgE efficiently reduced serum IgE without affecting other isotypes. Anti–M1′ domain was an effective prophylactic and therapeutic therapy in murine models of allergic asthma and helminth infection (136). Despite yielding a significant reduction of total and allergen-specific IgE, quilizumab treatment did not impact asthma exacerbations, lung function, and symptom scores in a phase II trial that included 578 patients with inadequately controlled allergic asthma (138). Quilizumab reduced circulating IgE antibodies between 30% and 40%, while omalizumab treatment resulted in an 89% to 98% reduction (129). This indicates that targeting membrane IgE is not sufficient to remove the allergen-specific IgE to a degree that confers clinical improvement. Therefore, other potential compartments of IgE memory appear to play a key role in the production of clinically relevant, allergen-specific IgE. These may include long-living plasma cells or subpopulations of memory B cells of other isotypes that can undergo a secondary switch to IgE upon reactivation.

MEDI4212, another IgE-targeting biologic, binds to soluble and membrane IgE. The main potential advantage of this approach is that it may achieve an immediate clinical benefit by directly targeting free IgE, while limiting the generation of new IgE-switched B cells and plasma cells (ref. 139 and Figure 3). In a phase I study, atopic individuals were treated with a single dose of MEDI4212, omalizumab, or placebo. MEDI4212 treatment decreased serum IgE more rapidly than omalizumab treatment, but IgE recovery was also much more rapid than in the omalizumab-treated group (140). The short-lived suppression of serum IgE in MEDI4212-treated patients corresponded with a rapid decrease in serum levels of the therapeutic antibody, a feature that limits the potential for dosing-schedule advantages over omalizumab.

A recent study showed that in a mouse model of peanut allergy and anaphylaxis, clinically relevant IgE titers were not sustained by long-living plasma cells but rather by allergen-specific memory
B cells that replenish the IgE-switched plasma cell compartment (141). It remains to be determined whether the same applies to other models and how this finding translates to the human system. Notably, treating AD patients with the anti-CD20 antibody rituximab, which depletes all circulating B cells (but only a fraction of B cells in various tissues), did not result in a reduction of allergen-specific IgE 4 to 8 weeks after treatment. This suggests that plasma cells can maintain IgE production for weeks to months without replenishment from circulating memory cells, or, alternatively, that tissue-resident memory B cells can replace circulating cells following depletion (142). Strategies that target these populations could be considered but may cause undesired side effects, because broadly targeting plasma cells or major memory B cell populations will impair protective humoral immunity against pathogens.

Conclusion

Allergies affect almost 1 billion people worldwide (143). A balance between immune tolerance and immune effector functions of innate and adaptive immune response has been shown to be decisive in allergy development and treatment. Various models have been used to study the mechanisms of immune tolerance, including AIT in patients, beekeepers, and cat owners who are chronically exposed to high doses of allergens. In addition to allergy vaccines, strategies to induce immune tolerance, such as directed therapies that target specific mediators of allergic reactions, show great promise. Humanized antibodies that target essential cytokines, cytokine receptors, and soluble or membrane-bound IgE are promising approaches to the treatment of asthma, AD, allergic rhinitis, and food allergy, some of which are in clinical use. These approaches can be categorized by their modulation of type 2 immunity: targeting the classical Th2 effector molecules by interfering with IL-4 and IL-13; interfering with eosinophil responses by targeting IL-5; interfering with Th2 and mast cell responses by targeting IL-9; fighting the itch response by targeting IL-31; and interfering with epithelium–immune cell interaction by targeting IL-25, IL-33, and TSLP, or by targeting soluble or cell surface–bound IgE. It should be noted here that downregulation of a general type 2 response may have certain consequences for immune responses in which Th2 cells, eosinophils, and type 2 effector cytokines such as IL-4, IL-5, and IL-13 play a role. Parasitic infections and downregulation and control of extensive type 1 immune responses that are dominant in autoimmunity represent two main conditions that must be sorted out in multicenter studies. All of these effector molecules target upstream or downstream events in type 2 immune response, omitting only a fraction of patients who lack a predominant type 2 immune response. Patients with non-type 2 response, such as intrinsic type of AD, non-eosinophilic asthma, CRS without nasal polyps, neutrophilic asthma, and obesity-induced asthma, have not so far been efficiently targeted with biologics. While there are obvious similarities, there are also evident clinical, immunological, and pathological divergences between asthma, allergic rhinitis, nasal polyps, food allergy, and EoE. Current approaches targeting type 2 immunity seem to affect overlapping patient groups and produce similar final physiopathological outcomes. Extensive research in the area is needed, and given the rapid developments in such a short time, a brighter future is ahead for a variety of allergic diseases.

Acknowledgments

Funding is provided by the Center for Allergy Research and Education (CARE) of Switzerland (to CK) and the Swiss National Science Foundation (grant 320030-159870, 310030_179428).

Address correspondence to: Mübeccel Akdis, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Obererstrasse 22, CH-7270 Davos Platz, Switzerland. Phone: 41.0.814100848; Email: akdism@siaf.uzh.ch.

50. Stassen M, et al. Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory-


